Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CSII. ST. PAUL, Minn.--(BUSINESS WIRE)--
Cardiovascular Systems, Inc. (CSII):
Revenues rose to $23.3 million in the fiscal 2013 first quarter, up 25 percent over the first quarter of fiscal 2012
Office-based lab revenues continued to grow at a double-digit consecutive quarter rate over the fourth quarter of fiscal 2012
Stealth 360°® revenues grew to 90 percent of total device revenues
Presentations at TCT conference reveal that moderate/severe calcification in coronary arteries is associated with higher complication rates, including a significantly higher incidence of death, highlighting a critical need for new treatment technologies
ORBIT II coronary trial endpoints are designed to demonstrate CSI technology’s ability to meet this need
Trial enrollment is 93 percent completed, with only 33 patients remaining
CONFIRM series, presented at VIVA’s late-breaking data session, shows that CSI’s orbital atherectomy system safely and effectively removes plaque in calcified peripheral lesions
http://finance.yahoo.com/news/cardiovascular-systems-reports-fiscal-2013-200000157.html
DVA. DaVita 3rd Quarter 2012 Results & Guides.
http://finance.yahoo.com/news/davita-3rd-quarter-2012-results-190100584.html
Thanks cheeky. LPH. Longwei Petroleum Provides Shareholder Update
http://ih.advfn.com/p.php?pid=nmona&article=54744088&symbol=LPH
Big Board Bios. Update:
[StocksDiva]
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=80989714
Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced the U.S. FDA granted priority review to the New Drug Application (NDA) filed at the end of August 2012 for Stivarga® (regorafenib) tablets to treat patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with two kinase inhibitors.
The submission was based upon data from the pivotal, global Phase III GRID study.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC (HiltonolTM). CDX-1401 is a fusion protein consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. The NY-ESO-1 antigen is expressed in a variety of cancer cells. Targeting protein antigens to the DEC-205 receptor on dendritic cells was pioneered by the late Ralph Steinman, MD, a member of Celldex's Scientific Advisory Board.
Dr. Steinman received the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and its role in adaptive immunity. In preclinical studies, CDX-1401 has been shown to induce potent and broad immunity. The Phase 1 study of CDX-1401 is the first clinical study to demonstrate that an off-the-shelf vaccine that targets dendritic cells in vivo through DEC-205 can safely lead to robust humoral and cellular immunity when combined with TLR agonists in cancer patients - overcoming a significant challenge in the development of protein based vaccines.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2012 on Monday, November 5, 2012, after the U.S. financial markets close.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that, due to severe weather on the East Coast of the United States, it will postpone its third quarter 2012 financial results press release and conference call to Wednesday, October 31, 2012 at 8:30 a.m. ET.
Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, announced that David Lewis, Ph.D., Vice President Biology and Site Head of its Madison, WI research and development facility will present data today at the 8th Annual Meeting of the Oligonucleotide Therapeutics Society in Boston.
AstraZeneca (NYSE:AZN) today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy.
BIOLASE, Inc. (NASDAQ: BIOL), the World's leading biological dental laser manufacturer and distributor, today announced that the Company will host a conference call on Monday, November 5th, at 4:30 p.m. Eastern Standard Time to discuss its operating results for the third quarter and nine months ended September 30, 2012, and to answer questions.
BIOLASE, Inc. (NASDAQ: BIOL), the World's leading biological dental laser manufacturer and distributor, today announced that the Company will host a conference call on Monday, November 5th, at 4:30 p.m. Eastern Standard Time to discuss its operating results for the third quarter and nine months ended September 30, 2012, and to answer questions.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC (HiltonolTM).
Compugen Ltd. (NASDAQ:CGEN) announced today the postponement of both the issuance of its Third Quarter 2012 Financial Results Report and conference call with investors to Monday, November 5, 2012 at 10 a.m. ET.
Dendreon Corporation (Nasdaq: DNDN) today announced that in light of Hurricane Sandy, the Company has rescheduled the release of its third quarter 2012 earnings results.
Depomed, Inc. (NASDAQ: DEPO) today announced that it will release third quarter fiscal year 2012 financial results after the market closes on Monday, November 5, 2012.
Today PlanPrescriber (www.planprescriber.com), a wholly owned subsidiary of eHealth, Inc. (NASDAQ: EHTH), released a list of nine costly mistakes that people typically make when trying to enroll in a Medicare Advantage plan. PlanPrescriber provides educational and comparison tools for Medicare insurance products that allow customers to compare Medicare products side-by-side, connect with knowledgeable, licensed agents, and enroll in select products online or over the phone.
GTx, Inc. (Nasdaq: GTXI) today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.
Haemonetics Corporation (NYSE: HAE) today reported second quarter 2013 net revenue of $218.2 million, up 22%, GAAP net income of $6.5 million, down 53%, and diluted earnings per share of $0.25, down 53%.
iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced growing demand for and adoption of its Xoft® Axxent® Electronic Brachytherapy System® for intraoperative radiation therapy (“IORT”).
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, featured its procedural solutions and sophistication from years of experience in lateral approach spine surgery at the North American Spine Society (NASS) 2012 Annual Meeting.
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that it has rescheduled its third quarter 2012 financial report and conference call due to Hurricane Sandy.
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today that it has rejected the revised and unsolicited, non-binding proposal from Matrixx Initiatives, Inc. ("Matrixx") to acquire the Company for $1.60 per share in cash.
Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced the launch of a redesigned website for China, www.sigmaaldrich.com/china, which offers more relevant content, improved search results, enhanced product detail pages and a completely translated homepage.
Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced its operating results for the third quarter ended Sept. 30, 2012.
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today that it has entered into definitive stock purchase agreements with accredited investors to raise approximately $10.8 million in a private placement financing.
Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, will hold a conference call on Monday, November 12, 2012 at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2012.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has rescheduled its third quarter 2012 earnings press release and conference call, which were originally scheduled for today, Monday, October 29.
CRY. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
Increases Full Year 2012 Revenue and EPS Guidance
Updated dial-in information for the 10 a.m. teleconference is contained in the press release below
Third Quarter Highlights:
- Total revenues grew 13% year-over-year to $33.4 million
- Product revenues grew 13% year-over-year to $16.9 million
- Tissue processing revenues grew 12% year-over-year to $16.4 million
- EPS of $0.06, or $0.08 on a non-GAAP basis
- Generated $6.1 million in cash flow from operations
- Initiated $0.025 per share quarterly dividend
http://finance.yahoo.com/news/cryolife-reports-13-revenue-growth-120400403.html
Halloween is my life long birthday.
SIAL. ascending/triangle.
http://stockcharts.com/h-sc/ui?s=SIAL&p=W&yr=1&mn=0&dy=0&id=p57961078776
SAFC Enters South Korean BioPharma Market with CrystalGenomics Agreement
SAFC Pre-formulation Services to Support Next-generation NSAID Product Development
http://finance.yahoo.com/news/safc-enters-south-korean-biopharma-110000929.html
SPNC. Spectranetics Achieves Third Quarter Revenue of $35.2 Million
10% Increase Over Q3 2011; 11% Constant Currency Growth Updates 2012 Outlook
http://finance.yahoo.com/news/spectranetics-achieves-third-quarter-revenue-100000160.html
RDY. Key Highlights (Q2 FY13)
http://finance.yahoo.com/news/dr-reddy-q2-h1-fy13-094000694.html
Consolidated revenues for Q2 FY13 at Rs. 28.8 billion, recorded YoY growth of 27%. Consolidated revenues for H1 FY13 at Rs. 54.2 billion, recorded YoY growth of 28%.
Revenues from the Global Generics segment for Q2 FY13 at Rs. 20.1 billion, recorded YoY growth of 25% primarily driven by North America, India and other emerging markets.
Revenues from the PSAI segment for Q2 FY13 at Rs. 7.9 billion, recorded YoY growth of 33%.
EBITDA for Q2 FY13 at Rs. 7.7 billion, 27% of revenues, recorded YoY growth of 47%. EBITDA for H1 FY13 at Rs. 12.7 billion, 23% of revenues, recorded YoY growth of 35%.
PAT for Q2 FY13 at Rs. 4.1 billion, 14% of revenues, recorded YoY growth of 32%. PAT for H1 FY13 at Rs. 7.4 billion, 14% of revenues, recorded YoY growth of 30%.
*Adjusted PAT for Q2 FY13 at Rs. 4.9 billion, 17% of revenues, recorded YoY growth of 77%.
During the quarter, the company launched 18 new generic products, filed 11 new product registrations and filed 10 DMFs globally.
Glassy, you think SRS has a bounce coming? EOM
HGR. Hanger, Inc. Announces 2012 Year To Date Acquisitions Totaling $35.6 Million Of Annual Net Revenue
http://finance.yahoo.com/news/hanger-inc-announces-2012-date-110000326.html
CTRX. Catamaran Corporation Receives Two Prestigious Awards for Innovative Healthcare Tools
http://finance.yahoo.com/news/catamaran-corporation-receives-two-prestigious-110000996.html
MRGE. Resurgens Orthopaedics Selects Merge Honeycomb(TM) for Image Archiving
Cloud-Based Solution Provides Cost Effective Long-Term Solution for Storing Patient Images
http://finance.yahoo.com/news/resurgens-orthopaedics-selects-merge-honeycomb-110000236.html
DOX. Amdocs Launches Cloud-Based eHealth Solutions to Give Service Providers Fast Entry to Growing Market
Solutions enable operators to capture new revenue streams in strategic and fast growing market; professional and consumer applications that monitor the chronically ill and elderly in their own homes
HAE. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
http://finance.yahoo.com/news/haemonetics-reports-second-quarter-fiscal-100000537.html
Big Board Bio Updates StocksDiva.
http://investorshub.advfn.com/StocksDiva-Bio-Bin-16112/
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced Watson has launched a generic version of Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval today from the U.S. FDA. Watson began shipping the product immediately.
On August 15, 2012, Watson announced that it had filed suit against the FDA challenging the Agency's decision regarding Watson's entitlement to shared exclusivity for its generic version of Actos®. Mylan Pharmaceuticals, Inc. subsequently intervened as a defendant in the action. On October 22, 2012, the U.S. District Court for the District of Columbia granted summary judgment in favor of Watson and ordered the FDA to approve Watson's ANDA. Mylan appealed the judgment to the U.S. Court of Appeals for the District of Columbia Circuit. The Court of Appeals has denied Mylan's motion for a stay of the judgment pending the appeal.
Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced they have entered into a settlement agreement with Hetero Labs Ltd. and Hetero USA Inc. (collectively, “Hetero”) in patent infringement litigation brought by Forest in response to Hetero's ANDA seeking approval to market generic versions of Forest's BYSTOLIC® (nebivolol) tablets. Specifically, under the terms of the settlement agreement and subject to review of the settlement terms by the U.S. Federal Trade Commission, Forest will provide a license to Hetero that will permit it to launch its generic version of BYSTOLIC® as of the date that is the later of (a) three calendar months prior to the expiration of U.S. Patent No. 6,545,040, including any extensions and/or pediatric exclusivities or (b) the date Hetero receives final FDA approval of its ANDA, or earlier in certain circumstances.
Similar patent infringement litigation brought by Forest against Alkem Laboratories, Ltd., Indchemie Health Specialties Pvt. Ltd., Glenmark Generics Inc., Watson Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Amerigen Pharmaceuticals Ltd., and related companies and subsidiaries, remains pending in a multidistrict litigation established in the U.S. District Court for the Northern District of Illinois.
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended September 30, 2012 before the U.S. financial markets open on Thursday, November 1, 2012.
Columbia Laboratories Inc. (Nasdaq: CBRX) today confirmed that the U.S. Food and Drug Administration (FDA) has denied Watson Pharmaceuticals’ (NYSE:WPI) Formal Dispute Resolution Request (FDRR) related to its New Drug Application (NDA 22-139) for Prochieve for the prevention of preterm birth in women with a short cervical length.
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will give a company presentation at the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum on Tuesday, October 30.
Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it will present at the American Association for the Study of Liver Disease (AASLD) Annual Meeting on November 12, 2012, in Boston, MA.
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today reported financial results for the three-month period ended September 30, 2012 – the first quarter of the Company’s 2013 fiscal year – and provided an update on the Company.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2012.
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the PCM® Cervical Disc System.
Repligen Corporation (NASDAQ:RGEN) today announced that it will report financial results for the third quarter of 2012 before the NASDAQ Global Market opens on Thursday, November 8.
RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, surgical specialties and other biologic implants, is launching a new biologic implant for use in sports medicine, orthopedic and spine surgeries.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved SYNRIBO (omacetaxine mepesuccinate) for Injection to treat adult patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).
Yes you and I both like DDD! Motley Fool Stock Advisor recommended it to me and they do have some great picks imo!
bigstocks. You know I like DDD.
Thanks Poem Stone! Will check the iBox. DDD AND SSYS both doing great for me-- 3-D printing cos. both.
3 nice after/hours PRs iBoxed.
Friday after/hours now iboxed. JBSS.
Thursday nooner & after/hours:
12:00pm AET. 3rd-Quarter Net Rises 1.8%; Raises Year View
4:00pm.STS. Reports Improved 2012 Third-Quarter Earnings
4:05pm. RMD. Record Financial Results for the Quarter Ended September 30, 2012
4:24pm. CB. Chubb Profit Climbs 79% to $533 Million on Disaster Costs
FB~NLOD 21.93 hovering right above that now...
from what I read, Mark Z expedited the employees lock up by 2 weeks- so they can start selling earlier- Monday and you can BET they are chomping at the bit!Also, its like they get early selling time not getting caught up in the 1Billion share selling later in Nov-wow
xero90. Laptop is getting hot again.
Hasn't done that for a couple weeks.
Think I will take a short nap with the hound dog
and get back for iBox after/hours.
I think you are right glassy.
Thanks! SIA. nice work there.
Very true... EOM
FB~ looks like a good short into the fade today and Mondays lock up expiration. Then a steady decline up to Nov 14 when the huge load comes unlocked-IMO. 22.20 at the moment
Nice after/hours iBox tonight.
Surprised to see it not doing much after hours! http://www.nasdaq.com/symbol/pfe/after-hours
PFE. Pfizer Declares A 22-Cent Fourth-Quarter 2012 Dividend
http://finance.yahoo.com/news/pfizer-declares-22-cent-fourth-180000089.html
Thank you my friend
I am trying my best, ha ha! I actually have a bid in for SATC at .48- not sure I will not pull it but maybe.....
You just making that money...
Yesterday's after-hours:
4:02pm. DYAX. revenues for the third quarter ended September 30, 2012 were $13.1 million, as compared to $10.1 million for the comparable quarter
4:03 pm. FLR Awarded Power Maintenance Services Contract at Multiple Sites for OG&E
AONE- ok in at .119 yesterday and out at .142 for now- BB EOD
excellent! welcome :)
Thanks My friend!!!
Welcome carp1 as a mod on Index Prime.
Poem Stone--- Thanks for your PM. I appreciate your kind offer but afraid I do not have enough time to devote to being a mod as I work full time. I wouldn't want to not do it justice. So I am sorry I am going to pass. I appreciate your offer though. Thanks for the tip as well! Good luck and best wishes! I always appreciate your excellent posts.
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
564
|
Created
|
09/23/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |